Vaccination with anti-idiotype antibody ganglidiomab mediates a GD2-specific anti-neuroblastoma immune response

Anti-GD2 strategy in the treatment of neuroblastoma

(2014) R.K. Yang et al.   DRUGS OF THE FUTURE

Recent advances in developing synthetic carbohydrate-based vaccines for cancer immunotherapies

(2012) Rachel Hevey et al.   Future Medicinal Chemistry

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

(2011) C. U. Louis et al.   BLOOD

NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin

(2011) Ruth Esser et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study

(2010) Suzanne Shusterman et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

(2010) Alice L. Yu et al.   NEW ENGLAND JOURNAL OF MEDICINE

A rationally designed tyrosine hydroxylase DNA vaccine induces specific antineuroblastoma immunity

(2008) N. Huebener et al.   MOLECULAR CANCER THERAPEUTICS